Men who were given the antipsychotic Risperdal as adolescents and suffered side effects may still be eligible to file lawsuits against manufacturer Janssen Pharmaceuticals. Risperdal was approved in 1993, and though a study documenting the link between Risperdal and male breast growth was not published until 2006, Janssen allegedly knew of the risks prior to the study.
Risperdal has been linked to an increased risk of breast tissue growth in boys and young men, also known as gynecomastia. A 2006 study found that Risperdal increases levels of a hormone known as prolactin, which can lead to breast tissue growth in boys. As many as 25% of cases of gynecomastia are linked to medications such as Risperdal.
Risperdal is given to a large number of foster children to treat symptoms of ADD and ADHD, although studies show the drug only treats symptoms and is not a cure. Boys who are given Risperdal could face increased prolactin levels for at least 2 years after medication stops.